Laprovitera N.; Salamon I.; Gelsomino F.; Porcellini E.; Riefolo M.; Garonzi M.; Tononi P.; Valente S.; Sabbioni S.; Fontana F.; Manaresi N.; D'Errico A.; Pantaleo M.A.; Ardizzoni A.; Ferracin M., Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches, «FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY», 2021, 9, Article number: 666156 , pp. 1 - 15 [Scientific article]Open Access
Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna, IFN-γ and CD38 in Hyperprogressive Cancer Development, «CANCERS», 2021, 13, Article number: E309 , pp. 1 - 24 [Scientific article]Open Access
Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ardizzoni, Andrea; Santoni, Matteo, Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [Scientific article]
Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M., Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [Scientific article]
Comito F.; Nigro M.C.; Sperandi F.; Melotti B.; Ardizzoni A., Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab, «EUROPEAN JOURNAL OF CANCER», 2021, 146, pp. 84 - 86 [Scientific article]
Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F., Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials, «EUROPEAN UROLOGY FOCUS», 2021, 1077, pp. 1 - 8 [Scientific article]
Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco, Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, Article number: 153410 , pp. 1 - 5 [Scientific article]
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19 , pp. 1 - 13 [Scientific article]Open Access
Laprovitera N.; Riefolo M.; Porcellini E.; Durante G.; Garajova I.; Vasuri F.; Aigelsreiter A.; Dandachi N.; Benvenuto G.; Agostinis F.; Sabbioni S.; Berindan Neagoe I.; Romualdi C.; Ardizzoni A.; Trere' D.; Pichler M.; D'Errico A.; Ferracin M., MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary, «MOLECULAR ONCOLOGY», 2021, 15, pp. 2732 - 2751 [Scientific article]Open Access
Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A., PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis, «FUTURE ONCOLOGY», 2021, 17, pp. 4415 - 4424 [Scientific article]
Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2021, 160, Article number: 103302 , pp. 1 - 5 [Scientific article]
Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [Scientific article]
Minari R.; Bonatti F.; Mazzaschi G.; Dodi A.; Facchinetti F.; Gelsomino F.; Cinquegrani G.; Squadrilli A.; Bordi P.; Buti S.; Bersanelli M.; Leonetti A.; Cosenza A.; Ferri L.; Rapacchi E.; Quaini F.; Ardizzoni A.; Tiseo M., PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors, «TUMORI», 2021, 00(0), pp. 1 - 9 [Scientific article]
Gelsomino F.; Facchinetti F.; Sisi M.; Zielli T.; Tiseo M.; Ardizzoni A., PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination, «IMMUNOTHERAPY», 2021, 13, pp. 363 - 369 [Scientific article]
Pellegrino B.; Cavanna L.; Boggiani D.; Zamagni C.; Frassoldati A.; Schirone A.; Caldara A.; Rocca A.; Gori S.; Piacentini F.; Berardi R.; Brandes A.A.; Foglietta J.; Villa F.; Todeschini R.; Tognetto M.; Naldi N.; Bortesi B.; Montemurro F.; Ardizzoni A.; Boni L.; Musolino A., Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), «ESMO OPEN», 2021, 6, Article number: 100019 , pp. 1 - 8 [Scientific article]Open Access
